Adaptive Clinical Trials for Breast Cancer · activity area

structure

2 child clusters

Sub-clusters inside Adaptive Clinical Trials for Breast Cancer. Each card links to its own detail page; counts are rolled up through the whole subtree of that child.

Adaptive Platform Trials for Breast Cancer Therapies

program type 11 activities

I-SPY 2 Trial Biomarker and Imaging Monitoring

program type 10 activities

organizations

1 orgs in this cluster's subtree

Every organization with primary activities in Adaptive Clinical Trials for Breast Cancer or any of its descendants. Click a column header to sort. Filter by name or state above the table.

showing 1 of 1

#	Organization	State	Revenue	Activities ↓
1	QUANTUM LEAP HEALTHCARE COLLABORATIVE Quantum Leap Healthcare Collaborative is an operational research organization that designs and implements adaptive clinical trials, primarily focusing on breas…	CA	$47.3M	21

theories of action

strategies used in this cluster

Theories of action extracted from orgs in this subtree. Click any to see the full set of orgs running the same approach.

Neoadjuvant Rapid Evaluation 1 org

By administering investigational therapies in the neoadjuvant setting before surgery, organizations can rapidly assess tumor response and accelerate treatment validation, because early biological changes in the tumor provide faster readouts of drug efficacy than long-term clinical outcomes. This strategy leverages the neoadjuvant window—treatment before surgery—as a biological testing ground to evaluate drug effectiveness in real time, using pathological and imaging biomarkers to measure response within weeks rather than waiting years for recurrence data. Unlike traditional adjuvant trials that require long follow-up periods, this approach shortens the drug evaluation timeline and enables adaptive learning within platform trials like I-SPY 2, making it a cornerstone of precision oncology and adaptive trial design.

QUANTUM LEAP HEALTHCARE COLLABORATIVE